Page last updated: 2024-12-07

2-aminoimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Aminoimidazole is a heterocyclic organic compound that serves as a building block in the synthesis of various biologically important molecules. It is a precursor to purine bases, adenine and guanine, essential components of DNA and RNA. The compound can be synthesized through various methods, including the reaction of formamide with glyoxal or the condensation of ethylenediamine with formamide. Notably, 2-aminoimidazole plays a crucial role in the biological synthesis of purines. It is studied extensively in research related to purine metabolism, the development of anticancer drugs, and the understanding of genetic diseases. 2-Aminoimidazole has also been investigated for its potential as a therapeutic agent for treating diseases such as cancer and HIV.'

2-aminoimidazole: from catabolism of arginine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID82140
CHEMBL ID291627
MeSH IDM0063903

Synonyms (34)

Synonym
AC-051
2ai ,
BB 0262960
einecs 231-751-4
AL-398/25017027
7720-39-0
1h-imidazol-2-ylamine
2-aminoimidazole
1h-imidazol-2-amine
inchi=1/c3h5n3/c4-3-5-1-2-6-3/h1-2h,(h3,4,5,6
AKOS000112995
CHEMBL291627 ,
FT-0650418
bdbm50316608
1h-imidazol-2-yl-ammonium
STL146908
AB07116
3MJL
2-amino imidazole
AM82001
BBL029017
1h-imidazole-2-amine
DTXSID60227953
Q-200237
2-aminoimidazole, aldrichcpr
CS-0054070
4-amino-2,6-dinitrobenzoicacid
mfcd00792530
Q27452839
P10144
EN300-27739
SY046108
HY-W062216
PD158409

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In this study, we evaluated the toxic effects of three of our most effective 2-aminoimidazole compounds (dihydrosventrin, RA, and SPAR) using a rapid pipeline that combines a series of assays."( Evaluation of the toxicity of 2-aminoimidazole antibiofilm agents using both cellular and model organism systems.
Cavanagh, J; Mathies, LD; Melander, C; Piper, A; Richards, JJ; Rogers, SA; Stowe, SD; Thompson, R; Tucker, AT, 2012
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Arginase-1Homo sapiens (human)Ki3,600.00003,600.00003,600.00003,600.0000AID977610
Chain A, Arginase-1Homo sapiens (human)Ki3,600.00003,600.00003,600.00003,600.0000AID977610
Nitric oxide synthase, brain Rattus norvegicus (Norway rat)IC50 (µMol)65.00000.04004.16389.3000AID481093
Nitric oxide synthase, inducibleMus musculus (house mouse)IC50 (µMol)65.00000.00103.39119.6000AID481094
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
urea cycleArginase-1Homo sapiens (human)
adaptive immune responseArginase-1Homo sapiens (human)
arginine catabolic processArginase-1Homo sapiens (human)
negative regulation of T cell proliferationArginase-1Homo sapiens (human)
defense response to protozoanArginase-1Homo sapiens (human)
innate immune responseArginase-1Homo sapiens (human)
negative regulation of activated T cell proliferationArginase-1Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayArginase-1Homo sapiens (human)
positive regulation of neutrophil mediated killing of fungusArginase-1Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionArginase-1Homo sapiens (human)
arginine catabolic process to ornithineArginase-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingArginase-1Homo sapiens (human)
arginase activityArginase-1Homo sapiens (human)
manganese ion bindingArginase-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionArginase-1Homo sapiens (human)
extracellular spaceArginase-1Homo sapiens (human)
nucleusArginase-1Homo sapiens (human)
cytosolArginase-1Homo sapiens (human)
azurophil granule lumenArginase-1Homo sapiens (human)
specific granule lumenArginase-1Homo sapiens (human)
cytosolArginase-1Homo sapiens (human)
cytoplasmArginase-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID480920Inhibition of human recombinant full length arginase 1 expressed in Escherichia coli BL21(DE3) by fixed point assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I.
AID71567Inhibition of [3H]GABA binding to Gamma-aminobutyric acid (GABA-A) receptor isolated from rat brain homogenates at 5*10e-4 M1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Aryl diazo compounds and diazonium salts as potential irreversible probes of the gamma-aminobutyric acid receptor.
AID25595Dissociation constant was evaluated1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID26397Dissociation constant (pKa, calculated using GNN method)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.
AID481094Inhibition of mouse recombinant iNOS2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I.
AID25092Ionization constant (pKa)1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Direct prediction of dissociation constants (pKa's) of clonidine-like imidazolines, 2-substituted imidazoles, and 1-methyl-2-substituted-imidazoles from 3D structures using a comparative molecular field analysis (CoMFA) approach.
AID481093Inhibition rat recombinant nNOS2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (90)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.11)18.7374
1990's5 (5.56)18.2507
2000's15 (16.67)29.6817
2010's62 (68.89)24.3611
2020's7 (7.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.31 (24.57)
Research Supply Index4.51 (2.92)
Research Growth Index5.51 (4.65)
Search Engine Demand Index37.47 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (4.44%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other86 (95.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]